Anti-CD30 immunotherapy has been successfully applied as ADC (brentuximab vedotin) to r/r adult T-cell leukemia/lymphoma patients [297], and r/r CD30+ lymphoma patients [298], showing an especially good response in Hodgkin lymphoma and systemic ALCL cases. The gene discussed is TNFRSF8; the disease is T-cell leukemia.